06-11-2010: Protagen AG and Bayer Schering Pharma AG announced the closing of a cooperation contract for discovery of novel biomarkers in Endometriosis.

Endometriosis is a debilitating gynecological medical condition occuring in roughly 5% -10% of women worldwide. The golden standard of diagnosis is currently performed by laparoscopy, a visual inspection of the abdominal organs followed by surgical removal and examination of lesions. Aim of the current study is to evaluate the UNIarray® technology for discovery of autoantibody patterns for the predictive diagnosis of Endometriosis and to improve patient’s quality of life. Proteomic profiling of inflammation, angiogenesis and tissue re-modelling processes are becoming increasingly important to understand the biology of Endometriosis.

"Biopharmaceutical companies benefit from our UNIarray® approach, a proprietary technology platform with the goal to develop diagnostics based on indication-specific autoantibody patterns in blood samples from patients," said Dr. Peter Schulz-Knappe, CSO and Executive Vice President of Diagnostics at Protagen. "Indication specific autoantibody patterns are not only present in classical autoimmune diseases, but also in cancer, neurodegenerative disorders, and even in apparently healthy individuals."

Contact / Request information

Request further information free of charge:

Facts, background information, dossiers
  • autoimmune diseases
  • angiogenesis
More about Bayer
More about Protagen
  • News

    Protagen and Charles River Form Strategic Partnership

    Protagen AG and Charles River Laboratories International, Inc. are announce a strategic Marketing & Sales alliance. For Charles River Biopharmaceutical Services (BPS) the fast-growing demand for biopharmaceuticals testing requires an expert partner with a broad range of services. Charles R ... more

    Protagen AG and MicroDiscovery GmbH cooperate in biomarker development

    Dortmund based Protagen AG and MicroDiscovery GmbH, a bioinformatics company based in Berlin, have started a cooperation to identify and validate biomarkers for medically relevant diseases. „Our proprietary technology platform UNIarray® and MicroDiscovery’s certified software solutions for ... more

    Protagen Deepens Cooperation With Bayer Schering Pharma

    Protagen AG and Bayer Schering Pharma AG announced the closing of a cooperation contract for discovery of novel biomarkers in Endometriosis. Endometriosis is a debilitating gynecological medical condition occuring in roughly 5% -10% of women worldwide. The golden standard of diagnosis is c ... more

More about Bayer Schering Pharma
  • News

    Protagen Deepens Cooperation With Bayer Schering Pharma

    Protagen AG and Bayer Schering Pharma AG announced the closing of a cooperation contract for discovery of novel biomarkers in Endometriosis. Endometriosis is a debilitating gynecological medical condition occuring in roughly 5% -10% of women worldwide. The golden standard of diagnosis is c ... more

    Affimed joins the Molecular Imaging Technology Initiative

    Affimed Therapeutics AG announced the start of a collaboration project with Bayer Schering Pharma AG, the German Cancer Research Center (DKFZ) and other partners within the Molecular Imaging Technology Initiative launched by the German Federal Ministry of Education and Research (“BMBF”). A ... more

Most read news
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE